Biocon

Biocon was founded in 1978 with US$10,000 as the initial capital by a Kiran Mazumdar who was born to Gujarati parents in Bangalore.{{Cite web|last=Egan|first=Mary Ellen|title=Big Shot in Bangalore|url=https://www.forbes.com/forbes/2004/1018/088.html|access-date=2021-03-07|website=Forbes|language=en}}

{{Cite web |last=Katyal |first=Surabhi |date=2015-06-15 |title=6 Indian and Indian Origin Women in the list of Forbes 100 Most Powerful Women in the World |url=https://thebetterindia.com/25233/six-indians-indian-origins-made-list-forbes-powerful-women-world/ |access-date=2024-09-21 |website=The Better India |language=en-US}}

In 1979, Biocon became the first Indian company to manufacture and export enzymes to the US and Europe.{{Cite web|url=http://www.indianmirror.com/indian-industries/top-industries/biocon.html|title=Biocon, India's largest biotech company.|last=nimmi|website=www.indianmirror.com|language=en-US|access-date=8 February 2018}}

In 1989, Unilever acquired Biocon Biochemicals Ltd. in Ireland and merged it with its subsidiary Quest International. Biocon received US funding for proprietary technologies.

In 1994, Biocon established Syngene International as a custom research company.

During 1998, Unilever agreed to sell its shareholding in Biocon to the Indian promoters. Biocon became an independent entity.{{Cite book|url=https://books.google.com/books?id=a9WGAwAAQBAJ&q=1998%E2%80%94Unilever+agrees+to+sell+its+shareholding+in+Biocon+to+the+Indian+promoters.+Biocon+becomes+an+independent+entity&pg=PA214|title=Winning Strategies for Business|last=Baisya|first=Rajat K.|date=9 September 2010|publisher=SAGE Publications India|isbn=9788132106081|language=en}}

In 2001, Biocon became the first Indian company to be approved by the USFDA for the manufacture of lovastatin; PlaFractor was granted a US 2001 and worldwide patent.{{Cite book|url=https://books.google.com/books?id=az8D9OOvfF0C&q=biocon+Becomes+the+first+Indian+company+to+be+approved+by+USFDA+for+the+manufacture+of+lovastatin&pg=PA654|title=Strategic Management 10E|last=Pearce|date=2009|publisher=McGraw-Hill Education (India) Pvt Limited|isbn=9780070264380|language=en}}

In 2003, Biocon became the first company worldwide to develop human insulin on a pichia expression system.{{Cite web|url=https://www.brandindiapharma.in/pharmaceutical-companies-india/biocon-limited|title=Biocon Ltd: About Biocon Pharma Company Founder, CEO, Products & Contact Address|website=www.brandindiapharma.in|access-date=8 February 2018}}

In 2006, BIOMAb EGFR, the first indigenously developed humanised monoclonal antibody for head-and-neck cancer, was launched, and APJ Abdul Kalam inaugurated India's largest biotech-hub, Biocon Park.{{Cite web|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=95300|title=Dr. APJ Abdul Kalam Dedicates India\'s First Cancer Drug BIOMab EGFR to the Nation and Inaugurates India\'s Largest Biotech-Hub "Biocon Park" {{!}} Evaluate|website=www.evaluategroup.com|access-date=8 February 2018}}

In 2008, Biocon acquired a 70% stake in German pharmaceutical company AxiCorp GmbH.{{Cite web|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=149061§ionID=&isEPVantage=no|title=Biocon Acquires 70% Stake in German Pharmaceutical Company, AxiCorp: Biosimilars Will be Main Focus {{!}} Evaluate|website=www.evaluategroup.com|access-date=8 February 2018}}

During 2009, a Syngene-Bristol Myers Squibb research facility was established in Bengaluru.{{Cite book|url=https://books.google.com/books?id=aoHRAwAAQBAJ&q=syngene+bms+partnership+2009&pg=PA451|title=India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing|last=Burns|first=Lawton R.|date=13 January 2014|publisher=Cambridge University Press|isbn=9781107044371|language=en}}

Later in 2009, Mylan announced a strategic collaboration with Biocon to enter the global generic biologics market.{{Cite news|url=http://newsroom.mylan.com/press-releases?item=122588|title=Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market|work=MediaRoom|access-date=8 February 2018}}

In 2010, Biocon expanded to Malaysia, with a biopharmaceutical manufacturing and R&D facility established in Iskandar, Johor.{{Cite news|url=https://www.asianscientist.com/2011/09/pharma/biocon-limited-rnd-facility-bio-xcell-malaysia/|title=Biocon Limited To Build US$161 Million R&D Facility in Bio-XCell, Malaysia|date=11 September 2011|work=Asian Scientist Magazine {{!}} Science, technology and medical news updates from Asia|access-date=8 February 2018|language=en-US}}

In 2012, Abbott announced a collaboration with Syngene to open the first nutrition R&D center in India.{{Cite press release|url=https://www.prnewswire.com/news-releases/abbott-announces-collaboration-with-syngene-to-open-first-nutrition-rd-center-in-india-149948055.html|title=Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India|last=Abbott|website=prnewswire.com|language=en|access-date=8 February 2018}}

During 2013, Biocon launched the biologic drug ALZUMAb to treat psoriasis.{{Cite news|url=http://www.thehindubusinessline.com/companies/Biocon-unveils-biologic-drug-to-treat-skin-disorder/article20647520.ece|title=Biocon unveils biologic drug to treat skin disorder|work=@businessline|access-date=8 February 2018|language=en}}

During 2014, Biocon launched the first biosimilar drug, CANMAb, to treat breast cancer.{{cite web|url=http://timesofindia.indiatimes.com/business/india-business/Kiran-Mazumdar-Shaws-Biocon-develops-new-breast-cancer-drug/articleshow/29016754.cms |title=Kiran Mazumdar-Shaw's Biocon develops new breast cancer drug |work=The Times of India |date=18 January 2014 |access-date=19 January 2014}}

In 2015, Biocon launched a hepatitis-C drug in India under the brand name CIMIVIR-L.{{Cite news|url=http://www.livemint.com/Companies/78WwKeykyzx3G5X4AhcQKJ/Biocon-launches-hepatitisC-drug-in-India.html|title=Biocon launches hepatitis-C drug in India|last=Pilla|first=Viswanath|date=24 December 2015|work=livemint.com/|access-date=8 February 2018}}

In 2016, Biocon became the first Indian company to launch a biosimilar insulin glargine pen in Japan.{{Cite news|url=http://www.livemint.com/Companies/T3byt5dkq71gZoWez8fhRL/Biocons-partner-FUJIFILM-launches-insulin-glargine-in-Japan.html|title=Biocon's partner FUJIFILM launches insulin glargine in Japan|last=Pilla|first=Viswanath|date=15 July 2016|work=livemint.com/|access-date=20 December 2017}}

During 2016, Syngene set up an Amgen R&D center in Bangalore.{{Cite web|url=https://www.fiercebiotech.com/cro/indian-cro-syngene-sets-up-amgen-r-d-center-bangalore|title=Indian CRO Syngene sets up Amgen R&D center in Bangalore {{!}} FierceBiotech|website=www.fiercebiotech.com|date=6 September 2016 |language=en|access-date=8 February 2018}}

In 2017, Biocon's Insugen became the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.{{Cite web|url=https://www.biosimilardevelopment.com/doc/biocon-wins-myr-million-contract-for-insulin-from-moh-malaysia-0001|title=Biocon Wins MYR 300 Million Contract For Insulin From MoH Malaysia|website=www.biosimilardevelopment.com|language=en|access-date=20 December 2017}}

In 2017, USFDA approved Mylan-Biocon's biosimilar for the cancer drug Herceptin.{{Cite news|url=http://www.livemint.com/Industry/AdFKCQcZvRRXnToosfdMbO/US-FDA-approves-MylanBiocons-biosimilar-for-cancer-drug-He.html|title=US FDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin|last=Trivedi|first=Isha|date=2 December 2017|work=livemint.com/|access-date=8 February 2018}}

During 2018, Biocon and Mylan received the European Commission's approval to market the biosimilar insulin glargine.{{cite news |title=Biocon, Mylan get European Commission approval to market biosimilar insulin glargine|url=https://business.medicaldialogues.in/biocon-mylan-get-european-commission-approval-market-biosimilar-insulin-glargine/ |publisher= Business Medical Dialogues|date=30 March 2018 }}

During 2021, Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together.{{Cite news |last=Das |first=Sohini |date=2021-09-17 |title=Biocon Biologics, Serum Institute Life Sciences enter strategic alliance |work=Business Standard India |url=https://www.business-standard.com/article/companies/biocon-biologics-serum-institute-life-sciences-enter-strategic-alliance-121091700898_1.html |access-date=2022-03-23}} Another aspect of the deal involved Bicocon selling 15% of its biologics subsidiary to the Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.

During 2022, Biocon Biologics bought the biosimilar assets of Viatris for $3.34 billion.{{Cite web |last=Rajagopal |first=Divya |date=2022-03-01 |title=Biocon's unit buys biosimilar assets of Viatris for $3.34 billion |url=https://www.livemint.com/companies/biocons-unit-buys-biosimilar-assets-of-viatris-for-3-34-billion-11646075550724.html |access-date=2022-03-22 |website=mint |language=en}}

File:STR 6036.jpg

Biocon's CMD Kiran Mazumdar-Shaw joined Biocon in 1978. Her efforts in biotechnology have drawn global recognition both for the industry in India and for Biocon. She was called India's "biotech queen" by The Economist and India's "mother of invention" by The New York Times. She was named among Time magazine's 2010 100 most influential people in the world, not only due to her contribution to the biotech industry, but also because she gives back to the community. Shaw has been featured on the Forbes list of "The World's 100 Most Powerful Women" and in the Financial Times "Top 50 Women in Business" list.

Shaw is the recipient of several awards including the Nikkei Asia Prize, 2009 for Regional Growth, Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur, The Economic Times 'Businesswoman of the Year', the 'Veuve Clicquot Initiative For Economic Development For Asia, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, 'Technology Pioneer' recognition by World Economic Forum and the Indian Chamber of Commerce Lifetime Achievement Award. She has received two Indian national awards, the Padma Shri (1989) and Padma Bhushan (2005), for her pioneering efforts in industrial biotechnology.

Christiane Hamacher was appointed as the CEO of Biocon Biologic India Limited, with her term starting in March 2019.{{cite news|url=https://business.medicaldialogues.in/biocon-appoints-christiane-hamacher-as-ceo-of-biocon-biologics-india/|title=Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India|date=2 March 2019|work=Medical Dialogues}}

On 3 December 2019, Siddharth Mittal took over from Arun Chandavarkar, who retired as CEO and joint managing director of Biocon.{{cite news|date=3 December 2019|title=Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar|publisher=Medical Dialogues|url=https://business.medicaldialogues.in/biocon-names-siddharth-mittal-as-new-ceo-joint-md-bids-farewell-to-arun-chandavarkar/}}

In 2021, Hamacher resigned from her position, following differences with Kiran Mazumdar-Shaw.{{Cite web |last= |first= |date=2021-01-22 |title=Christiane Hamacher quits as CEO of Biocon Biologics |url=https://www.thehindubusinessline.com/companies/christiane-hamacher-quits-as-ceo-of-biocon-biologics/article33637778.ece |access-date=2024-09-21 |website=BusinessLine |language=en}}

File:Biocon Park .jpg, Bangalore]]

Biocon Biologics is Biocon's biosimilar subsidiary. In 2021, Biocon and Viatris received approval to launch Semglee, an insulin glargine-yfgn injection, the first interchangble biosimilar for diabetes in the United States.{{Cite web |date=2021 |title=Press Release titled "Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes" |url=https://www.biocon.com/docs/PressRelease_USFDA_BBL_Biocon_29072021.pdf |access-date=22 March 2022 |website=Biocon.com}} In 2021, Biocon sold 15% of Biocon Biologics to Serum Institute of India for a valuation of $4.9 billion, for which Biocon will receive access to 100 million doses of vaccines per annum for 15 years.{{Cite web |last=Biocon |date=16 September 2021 |title=Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance |url=https://www.biocon.com/biocon-biologics-and-serum-institute-life-sciences-announce-strategic-alliance/ |access-date=2022-04-23 |website=Biocon |language=en-US}} These vaccines will mainly be supplied from Serum Institute's upcoming vaccine facility in Pune, and Biocon will also have the commercialization rights of Serum Institute's vaccine portfolio, which includes the COVID-19 vaccine, for the international markets. In May 2022, Viatris sold its biosimilars division to Biocon Biologics for a price of US$3.335 billion.{{Cite web |last=Li |first=Robert |date=March 2, 2022 |title=Viatris sells biosimilars unit for USD 3.335 billion |url=https://iclg.com/ibr/articles/17681-viatris-sells-biosimilars-unit-for-usd-3-335-billion |access-date=March 31, 2022 |website=ICLG}}

Established in 1993, Syngene International Limited is a contract research and development organization (CDMO). In the CDMO space, Syngene primarily focuses on research innovation and manufacturing services for their clients.{{Cite web |last=Babu |first=Venkatesha |date=2021 |title=We are co-innovating with global pharma companies: Syngene MD & CEO |url=https://www.thehindubusinessline.com/companies/we-are-co-innovating-with-global-pharma-companies-syngene-md-ceo/article38031492.ece |access-date=2022-03-15 |website=www.thehindubusinessline.com |language=en}} The company has four divisions: drug discovery services, dedicated research centres, development devices and manufacturing. Syngene works with eight of the top 10 global pharma companies and, Syngene's clients include Amgen, Zoetis, GlaxoSmithKline and Bristol Myers Squibb.{{Cite web |last=Ghosh |first=Debojyoti |date=2021 |title=Syngene's winning formula |url=https://www.fortuneindia.com/enterprise/syngenes-winning-formula/105633 |access-date=2022-03-15 |website=www.fortuneindia.com |language=en}} Syngene has been expanding its operations. Since 2020, the company has opened an R&D centre in Hyderabad, is building an API manufacturing facility in Mangalore, which was scheduled to be commissioned in 2022, and has expanded their R&D facility in Bangalore.{{Cite web |last=Rughani |first=Kushal |date=10 February 2021 |title=Initiating Coverage: Syngene International Ltd |url=https://www.hdfcsec.com/hsl.research.pdf/Initiating%20Coverage%20-%20Syngene%20International_10022021.pdf |access-date=22 April 2022 |website=HDFC Securities |page=2 }} Syngene also provides biologics CDMO services.{{Cite web |last1=Khandekar |first1=Siddhant |last2=Thakur |first2=Raunak |date=21 January 2022 |title=Syngene International (SYNINT) |url=https://www.icicidirect.com/mailimages/IDirect_Syngene_Q3FY22.pdf |access-date=17 May 2022 |website=ICICI Direct |page=2 }} In July 2022, Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librela (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs.{{Cite web |last=Rautela |first=Isha |date=2022-07-14 |title=Syngene inks 10-year biologics manufacturing pact with Zoetis |url=https://www.thehindubusinessline.com/companies/syngene-inks-10-year-biologics-manufacturing-pact-with-zoetis/article65640179.ece |access-date=2022-07-17 |website=www.thehindubusinessline.com |language=en}} SynVent is Syngene's drug discovery and development platform for both small and large molecules.{{Cite web |title=SynVent Integrated Drug Discovery |url=https://www.syngeneintl.com/solutions/discovery/integrated-drug-discovery-solutions/ |access-date=24 July 2022 |website=Syngene International}} In September 2022, Biocon divested 5.4% of its shares in Syngene International.{{Cite web |last=Jaiswar |first=Pooja Sitaram |date=2022-09-06 |title=Biocon divests over ₹1,220 crore stake in Syngene International in bulk deal |url=https://www.livemint.com/market/stock-market-news/biocon-divests-over-rs-1-220-crore-stake-in-syngene-international-in-bulk-deal-should-you-buy-11662478237201.html |access-date=2022-09-08 |website=mint |language=en}}

Clinigene International Limited is a subsidiary of Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.

Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.

In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.{{Cite journal |date=2006-10-29 |title=Atlas Copco sells majority stake in rental business |url=http://dx.doi.org/10.1016/s1359-6128(06)71621-4 |journal=Pump Industry Analyst |volume=2006 |issue=10 |pages=12 |doi=10.1016/s1359-6128(06)71621-4 |issn=1359-6128|url-access=subscription }}

Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi.{{Cite web |title=Building on a Foundation of IP |url=https://www.wipo.int/ipadvantage/en/details.jsp?id=2602 |access-date=2023-03-20 |website=www.wipo.int |language=en}}

Biofusion Therapeutics Limited was incorporated in March 2021. It is 100% owned by Biocon.{{Cite web |title=Biocon incorporates wholly-owned subsidiary Biofusion Therapeutics |url=https://flipit.money/flips/biocon-incorporates-wholly-owned-subsidiary-biofusion-therapeutics |access-date=2023-03-20 |website=flipit.money |language=en}}

In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics. Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.

In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research. The goal of this collaboration is to develop a therapeutic vaccine where the T cell-mediated immunity is enhanced and maintained against a tumor that otherwise evades immune responses. Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied.

In 2009, Biocon signed a collaboration agreement with Viatris to develop and commercialize generic biologics. Viatris and Biocon will share development, capital, and other costs to bring products to market. Viatris will have exclusive commercialisation rights in the USA, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries through a profit-sharing arrangement with Biocon.

Biocon and Optimer Pharmaceuticals, a biopharmaceutical company focused on the treatment of serious infections such as Clostridioides difficile infection (CDI), have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, fidaxomicin.

Biocon is also developing fully human antibodies BVX 10 and BVX-20 with a US antibody technology partner, Vaccinex. The partnership was initiated in 2004. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients with rheumatoid arthritis. Biocon's strategic partnership with Vaccinex allows access to their proprietary human antibody platform technology, thereby providing a strong IP protection to Biocon's antibody pipeline.

In 2007, Biocon and Abraxis BioScience, Inc. entered into an agreement that helped Biocon out-license the rights to develop and market a biosimilar version of GCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets.

In January 2018, Sandoz (a Novartis division) announced a global partnership with Biocon to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology for patients worldwide.{{Cite web|url=https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation-biosimilars|title=Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars {{!}} Novartis|website=Novartis|language=en|access-date=8 February 2018}}

Biocon's manufacturing facilities are located at two sites in Bangalore.

Biocon's R&D focuses on the entire drug development pathway – from process development to non-clinical and clinical research.

Biocon offers 36 brands of products across the four therapeutic divisions of diabetology, nephrology, oncology, and cardiology.

{{Reflist|refs=

{{Cite web |url=http://www.biocon.com/docs/AR10-BIOCON.pdf |title=Biocon Annual Report, 2010 |access-date=20 September 2010 |archive-url=https://web.archive.org/web/20101026031837/http://biocon.com/docs/AR10-BIOCON.pdf |archive-date=26 October 2010 |url-status=dead }}

Kiran Mazumdar-Shaw, CMD, Biocon Ltd, [http://www.outlookmoney.com/article.aspx?88528 'Biotech Is Not for Punters'], Outlook Money, 15 July 2004

Biocon Website ({{cite web |url=http://biocon.com/ |title=Biocon - Biosimilars, Fermentation, Oral Insulin, Human Insulin, Immunosuppresants, Monoclonal Antibody, Recombinant Proteins, Biopharmaceutical, Biotechnology Company, EGFR, GCSF, Fermentation, Orlistat, Insulin Glargine, Insulin Lispro, Peptides, Insulin Aspart |access-date=3 August 2014 |url-status=dead |archive-url=https://web.archive.org/web/20140807042606/http://www.biocon.com/ |archive-date=7 August 2014 }})

Nature Reviews Drug Discovery, July 2010

Biospectrum India Friday, 11 July 2008

Kiran Mazumdar Shaw, India's fermentation queen, 30 August 2001

[https://www.nytimes.com/2003/08/16/world/the-saturday-profile-how-india-s-mother-of-invention-built-an-industry.html "How India's Mother of Invention Built an Industry"], 16 August 2003

Time, 29 April 2010

The World's 100 Most Powerful Women, Forbes, 19 August 2009

FT top 50 women in world business, Financial Times, 25 September 2009

The Hindu, 12 May 2009

}}

{{Commons category|Biocon}}

{{Contract research organization}}

{{Nifty 200 companies}}

{{Bangalore topics}}

{{Authority control}}

Category:Biotechnology companies of India

Category:Pharmaceutical companies established in 1978

Category:Pharmaceutical companies of India

Category:Manufacturing companies based in Bengaluru

Category:Biotechnology companies established in 1978

Category:Indian companies established in 1978

Category:Indian brands

Category:1978 establishments in Karnataka

Category:Companies listed on the National Stock Exchange of India

Category:Companies listed on the Bombay Stock Exchange